🚀 Intrepid Labs: Better medicine, fast.
We are really excited about our recent investment in Intrepid Labs, a groundbreaking Canadian startup that is revolutionising the drug development process. It is one out of three investments made so far from our recently established Fund 2.
Spun out of the University of Toronto in 2023, Intrepid Labs combines machine learning, robotics, and pharmaceutical science to address critical bottlenecks in drug formulation, making the process faster, more efficient, and less costly.
Intrepid Labs' proprietary tech leverages advanced AI and robotic automation to optimise drug formulations with unprecedented speed and precision. Their innovative approach not only accelerates the development of life-saving therapies but also opens up new possibilities for personalised medicine and the rescue of previously abandoned drug candidates.
We are proud to support Intrepid Labs' visionary founders, Dr. Christine Allen, Dr. Alán Aspuru-Guzik, Dr. Pauric Bannigan, and Dr. Riley Hickman, as they lead the charge in transforming the future of drug development. Their self-driving labs represent a significant leap forward in the pharmaceutical industry, much like how machine learning is accelerating design cycles in other complex product categories.
At Propagator Ventures, our mission is to back transformative deep-tech solutions that tackle grand global challenges. Intrepid Labs' technology aligns perfectly with this vision, and we are excited to see the impact they will make in the $1.4 trillion pharma value chain.
More details here on why we invested in Intrepid:
https://lnkd.in/gzmmxnqS
#IntrepidLabs #MachineLearning #AI #Robotics #PharmaceuticalScience #DrugDevelopment #Investment #DeepTech #Healthcare #BiotechnologyResearch #DrugFormulation